Can You Take Mushroom Supplements With Antidepressants?

Most common functional mushroom supplements, including lion’s mane, reishi, cordyceps, chaga, and turkey tail, have no well-documented dangerous interactions with standard antidepressants. That said, “no documented interaction” is not the same as “proven safe,” and the clinical research that would settle the question barely exists. The picture also changes dramatically if the mushroom in question contains psilocybin, the psychoactive compound in so-called magic mushrooms, which does interact with several classes of antidepressants in ways that range from blunting the psychedelic effect to raising genuine safety concerns.

The Distinction That Matters Most

When people ask about mushroom supplements and antidepressants, they could be asking about two very different categories. Functional or medicinal mushroom supplements are the capsules, powders, and tinctures sold in health food stores: lion’s mane for cognitive support, reishi for relaxation, cordyceps for energy, turkey tail for immune function. These contain no psilocybin. Psilocybin mushrooms, on the other hand, are a controlled substance in most jurisdictions and are increasingly being studied as a treatment for depression in their own right. The interaction profiles for these two categories have almost nothing in common, and conflating them leads to unnecessary fear in one direction and dangerous complacency in the other.

Functional Mushroom Supplements and Antidepressants

The honest answer about functional mushroom supplements taken alongside antidepressants is that we have very little clinical data either way. A comprehensive review of reishi, for instance, found pharmacological activity across a range of conditions in preclinical studies but noted that clinical studies on safety, efficacy, and interactions with other substances are largely missing.¹ That pattern repeats across most medicinal mushroom species: promising animal research, a handful of small human trials focused on the mushroom alone, and essentially zero controlled studies looking at what happens when you combine them with prescription medications.

This gap is not unique to mushrooms. Dietary supplements in general undergo far less interaction testing than pharmaceutical drugs. But it does mean that when a supplement brand says its lion’s mane or turkey tail product is “safe to take with medications,” that claim is based on the absence of reported problems rather than on rigorous testing. For commonly used mushroom species at typical supplement doses, no pattern of serious adverse events with antidepressants has emerged in published literature. That is reassuring but not conclusive.

Why Cordyceps Raises a Theoretical Concern

Among functional mushrooms, cordyceps deserves a closer look for anyone taking an antidepressant that affects serotonin. Cordycepin, the primary bioactive compound in Cordyceps militaris, has been shown in animal models to increase serotonin levels in the brain. One study using a menopause-related stress model in rodents found that cordycepin treatment significantly reduced depressive and anxiety-like behaviors and elevated serotonin and brain-derived neurotrophic factor (BDNF) in the hippocampus and cortex.²

If a supplement is boosting serotonin in the brain and you are already taking an SSRI or SNRI that keeps serotonin elevated, the theoretical question is whether you could end up with too much serotonin activity. In practice, no human case reports of serotonin toxicity from combining cordyceps supplements with antidepressants have been published. The doses used in animal studies are often much higher relative to body weight than what you would get from a standard supplement capsule. Still, the mechanism is worth knowing about, especially if you are taking high doses of cordyceps alongside a serotonergic antidepressant and notice symptoms like agitation, rapid heart rate, or muscle twitching, which are hallmarks of excess serotonin activity.

How Medicinal Mushrooms Affect the Brain

Understanding why researchers are even interested in mushrooms for mental health helps explain the potential for overlap with antidepressant mechanisms. A review of medicinal mushrooms’ antidepressant potential identified several pathways through which compounds in species like lion’s mane, reishi, and cordyceps appear to work. These include anti-neuroinflammatory and antioxidant effects that influence neurotrophin expression, the creation of new brain cells, and the gut-brain axis.³ In one rodent study, a water extract of the honey mushroom (Armillaria mellea) reduced brain inflammation markers and alleviated depressive behaviors at higher doses.⁴

Most antidepressants work primarily by altering neurotransmitter levels, particularly serotonin and norepinephrine. Medicinal mushrooms appear to operate through different and somewhat broader mechanisms, including reducing inflammation and supporting nerve growth factors. In theory, these complementary pathways could even be beneficial together. But “complementary in theory” and “proven safe in combination” are not the same thing. The concern is not just about direct pharmacological clashes but also about unpredictable additive effects when two substances are both nudging the same downstream brain chemistry.

Reishi and Sedation

Reishi is often marketed for sleep and relaxation, and preclinical research supports that it has sedative properties.¹ Several antidepressants, particularly mirtazapine, trazodone, and some tricyclics, also cause significant drowsiness. If you are taking one of those and adding a reishi supplement at bedtime, you might experience more sedation than expected. This is not a dangerous drug interaction in the traditional sense, but it is a practical consideration, especially if you drive or operate machinery in the morning. The same caution applies to combining reishi with any CNS depressant, including alcohol or benzodiazepines.

Psilocybin Mushrooms and SSRIs or SNRIs

The interaction picture shifts considerably when we move from functional mushroom supplements to psilocybin-containing mushrooms. The most consistent finding is that SSRIs and SNRIs dampen the psychedelic effects of psilocybin. A study analyzing over 600 reports from people who took psilocybin mushrooms while on an antidepressant found that about half of those on SSRIs and over half of those on SNRIs experienced weaker-than-expected effects. Those on bupropion, which works through different brain pathways, were less likely to report blunted effects.⁵ This dampening persisted even after people stopped their antidepressant, with the effect not fully resolving for three to six months after discontinuation.

This matters for two reasons. First, some people are stopping their antidepressants in order to have a full psychedelic experience, which is dangerous without medical supervision. Second, the persistence of the dampening effect means that even if you have recently tapered off an SSRI, psilocybin may not work as expected for months.

The Serotonin Toxicity Question

The fear that combining psilocybin with an SSRI could cause serotonin syndrome has circulated widely online. Psilocybin acts on the same serotonin receptors that SSRIs modulate, so the concern is not irrational. However, the clinical evidence so far is more reassuring than alarming. A scoping review covering ten studies that evaluated the safety of taking antidepressants alongside classic psychedelics found no confirmed cases of serotonin toxicity or serotonin syndrome.⁶ That said, the same review noted that one qualitative study found two reports out of 433 that were suggestive of severe serotonin syndrome, including seizure and muscle rigidity, though the authors could not confirm these because no hospital records were available.

A separate analysis of Reddit posts about combining SSRIs with psilocybin mushrooms found that about 8% of posts described negative physical or psychological effects, with 13 of those reports potentially reflecting serotonin toxicity and one concerning for a psychotic or manic episode.⁷ Self-reported Reddit data has obvious limitations, but it does suggest that while most people who combine the two do not experience a crisis, a small fraction may develop concerning symptoms.

The takeaway from the current evidence is that serotonin syndrome from psilocybin plus an SSRI is possible but appears to be rare. The more common outcome by far is that the antidepressant simply blunts the psychedelic experience. Neither outcome, though, should encourage anyone to adjust their antidepressant regimen without talking to a doctor.

MAOIs Are a Different Risk Category

Monoamine oxidase inhibitors, or MAOIs, are an older class of antidepressants that are well known for interacting with a wide range of foods and drugs. These medications prevent the breakdown of several neurotransmitters and also tyramine, a substance found in aged and fermented foods. Psilocybin mushrooms appear to carry a specific risk with MAOIs that goes beyond the usual serotonin concern. A published case report described a 42-year-old man who developed a hypertensive emergency, with severe blood pressure spikes, chest pain, and palpitations, roughly half an hour after taking a small dose of psilocybin mushrooms while prescribed the MAOI tranylcypromine along with an amphetamine-based medication. The investigators suspected that phenylethylamine, a compound naturally present in psilocybin mushroom species, interacted with the MAOI to trigger the dangerous blood pressure spike.⁸

This case involved multiple medications, so it is difficult to pin the reaction on the MAOI-psilocybin combination alone. But the underlying pharmacology is straightforward: MAOIs block the enzyme that normally breaks down phenylethylamine and other monoamines, so when an outside source of those compounds enters the body, levels can spike dangerously. Anyone on an MAOI should treat psilocybin mushrooms the same way they would treat aged cheese or cured meats: as a potential trigger for a hypertensive crisis. Whether common functional mushroom supplements contain meaningful amounts of phenylethylamine or other MAOI-interacting amines is not well characterized, which is yet another data gap in this space.

Bupropion Stands Apart

Bupropion (sold as Wellbutrin, among other names) works through dopamine and norepinephrine rather than serotonin, which gives it a different interaction profile from SSRIs and SNRIs. In the study on psilocybin attenuation mentioned earlier, people taking bupropion were significantly less likely to report blunted psychedelic effects compared to those on SSRIs or SNRIs.⁵ For functional mushroom supplements, the theoretical concern about stacking serotonin effects is also less relevant with bupropion, since neither the drug nor most mushroom compounds are primarily serotonergic in the way that SSRIs are.

That does not mean bupropion is interaction-free across the board. Bupropion inhibits certain liver enzymes involved in drug metabolism, and some mushroom extracts contain compounds that may also affect liver enzyme activity. But no specific clinical interaction between bupropion and any functional mushroom supplement has been documented.

The Quality Control Problem

Even if a given mushroom species is pharmacologically benign alongside your antidepressant, the product you are taking might not contain what it says on the label. Mushroom supplements are sold as dietary supplements, which in the United States means they are not subject to the same pre-market testing or standardization requirements as prescription drugs. Products can vary widely in the concentration of active compounds depending on whether they use the fruiting body or mycelium, how the extract was prepared, and whether any additional ingredients were included.

Some “mushroom blend” products combine multiple species in a single capsule, sometimes alongside other herbal ingredients like ashwagandha or rhodiola that have their own interaction profiles. If you are taking an antidepressant and want to add a mushroom supplement, choosing a single-species product from a manufacturer that provides third-party testing for identity and potency at least reduces one layer of uncertainty.

What to Tell Your Doctor

Physicians and pharmacists rely on interaction databases that are only as good as the clinical data feeding them. For most functional mushroom supplements, those databases will show no known interactions with antidepressants, because the studies have not been done. That blank space is not permission. It is an absence of information. If you bring up mushroom supplements with your prescriber, expect one of two responses: either they will not be familiar with the specific product and will give a generic caution, or they will look it up and find the same void of data.

The more useful conversation is about specifics. Tell your doctor which mushroom species you are taking or plan to take, at what dose, and in what form. Mention any changes you have noticed since starting the supplement, whether positive or negative. If you are considering psilocybin for depression, whether through a clinical trial or otherwise, that conversation is especially important given the evidence that it interacts with antidepressant classes in different ways and that stopping an antidepressant abruptly carries its own risks, including withdrawal symptoms and relapse.

When Preclinical Promising Does Not Mean Clinically Safe

A recurring theme in mushroom supplement research is the mismatch between exciting preclinical findings and the near-total absence of clinical interaction data. Animal studies show that compounds in lion’s mane promote nerve growth factor, that cordycepin lifts serotonin and BDNF, and that reishi extracts have sedative and anti-anxiety properties. These are interesting and plausible mechanisms. But animal pharmacokinetics, meaning how a substance is absorbed, distributed, and broken down, often differ substantially from what happens in a human body, and the doses used in rodent studies frequently do not translate directly to typical supplement doses.

The research community has recognized this gap. The review of medicinal mushroom antidepressant mechanisms explicitly called for more clinical work to validate the pathways identified in animal models.³ Until that work is done, anyone combining these supplements with antidepressants is essentially running an uncontrolled experiment on themselves. For most people taking standard doses of common mushroom supplements, the risk appears low. But “appears low based on limited data” is not the same reassurance as “has been tested and found safe,” and keeping that distinction in mind is the most honest thing you can do for your own health decisions.